Figure 2.
Kinetics of antibody responses against HPV-16 and HPV-18 (according to protocol immunogenicity cohort, initially seronegative subjects). CI, confidence interval; EU, ELISA unit; GMT, geometric mean titer. Natural infection, GMT in subjects who had cleared a natural infection (i.e., 29.8 [28.5 to 31.1] EU/mL for HPV-16 and 22.7 [21.7 to 23.7] EU/mL for HPV-18).3 Plateau, GMT at the plateau level (Month 45–50) in a study in which sustained protection with the HPV-16/18 AS 04-adjuvanted vaccine was shown up to 6.4 y after first vaccination (i.e., 397.8 [344.7 to 459.1] EU/mL for HPV-16 and 297.3 [258.2 to 342.2] EU/mL for HPV-18).2